SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.
Dividend stocks can be a great place to start looking. A couple of Dividend Kings that have been doing particularly well this year are AbbVie (NYSE: ABBV) and Altria Group (NYSE: MO). AbbVie is a top healthcare stock that yields 3.7% annually, which is more than double the S&P 500 average of less than 1.4%.
We highlight 3 ETFs with juicy dividend yields and excellent performance